A Case of Malignant Melanoma of the Oral Cavity Alive with Liver Metastasis for a Long Period with Administration of a Biologic Response Modifier, OK432

MASAHIRO UMEDA*, MAHO MURATA, HIROAKI SUZUKI, TADAHIKO YANAGIDA, YASUYUKI SHIBUYA, and TAKAHIDE KOMORI

Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, 7-5-1Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Received 17 September 2009/ Accepted 8 February 2010

Key Words: Malignant melanoma of the oral cavity, liver metastasis, biologic response modifier, OK432

A patient with malignant melanoma of the oral cavity who lived for a long period despite developing liver metastasis is presented. An 81-year-old female was referred to our hospital because of a pigmented tumor of the lower gingiva. Under the clinical diagnosis of malignant melanoma, she underwent bilateral functional neck dissection and marginal mandiblectomy. Histological diagnosis of the operation material was malignant melanoma with regional lymph node metastasis. In spite of loco-regional control, liver metastasis developed at 7 months after the surgery. She then underwent combination chemotherapies with dimethyl triazeno imidazole carboxamide (DTIC), nimustine hydrochloride (ACNU) and vincristin (DAV therapy), or cisplatin, DTIC, ACNU and tamoxifen (DAC-tam), but no marked response was obtained. Considering the advanced age of the patient, immunotherapy with a biological response modifier, OK432, alone was started. After administration of OK432, the metastatic tumor gradually decreased, and she is alive without any clinical symptoms of tumor at 46 months after the detection of liver metastasis, although it is still present on ultrasonic and CT examinations.

The frequency of malignant melanoma of the oral cavity among Japanese people is much higher than that among Caucasians. Nevertheless, the treatment method as well as the classification for oral melanoma remain controversial 30,32. We previously reported that oral melanoma patients can obtain a good prognosis when an appropriate therapy is used without a preoperative surgical procedure such as incisional biopsy or tooth extraction 33. However, the prognosis of patients with oral melanoma who developed distant metastases is extremely poor. We present here a new case of malignant melanoma occurring in the mandibular gingiva who has been alive for a long period despite liver metastasis with administration of a biological response modifier, OK432.
CLINICAL CASES

An 81-year-old female visited a dental clinic with a chief complaint of a black tumorous lesion with pain in the anterior mandibular gingiva. Her dentist extracted the left side lateral incisor, but the symptoms did not improve, and she was referred to our hospital 2 weeks later. Clinical examinations revealed a black nodule in the anterior mandibular gingiva surrounded by a black plaque and macular lesions (Fig. 1). Panorama X-ray showed alveolar bone resorption in the region of 1–3 (Fig. 2). No enlarged cervical lymph nodes and no metastases to the lung or liver were found by CT examinations. Under the clinical diagnosis of malignant melanoma, she underwent surgery.

Figure 1. Intraoral findings showing a black nodule surrounded by pigmented plaque and macular lesions in the mandibular gingiva.

Figure 2. Panoramic X-ray image shows diffuse bone resorption of the alveolar process of the mandible around the apical region of the left lateral incisor.
Since a black lymph node was observed in the right level IB neck during the operation, bilateral functional neck dissection and marginal mandiblectomy were performed. Resection was done at least 10 mm from the pigmented nodule and 5 mm from the macular lesion (Fig. 3). Histological examinations of the resected material showed malignant melanoma of the gingiva invading into the mandibular bone with a tumor thickness of 15 mm, and a single lymph node metastasis to the right level IB neck (Fig. 4).

**Figure 3.** Incision line of the intraoral tumor (arrows). Resection was done at least 5mm from the macular lesion. Bilateral functional neck dissection and marginal mandiblectomy were also performed.

**Figure 4.** Histological findings of the intraoral tumor (HE stain, original magnification X200).

She was free from loco-regional recurrence, but ultrasonic images showed liver metastasis at 7 months after surgery. One course of DAV therapy with dimethyl triazeno imidazole carboxamide (DTIC), nimustine hydrochloride (ACNU), and vincristine was
MALIGNANT MELANOMA OF THE ORAL CAVITY

performed. The following administration schedule was used: DTIC, 100 mg (day 1) and 200 mg (days 2-5); ACNU, 100 mg (day 1); vincristine, 1 mg (day 1). Further, another two courses of DAC-tam therapy with cisplatin (CDDP), DTIC, ACNU, and tamoxifen were added. The administration schedule was as follows: CDDP, 20 mg (days 1-3); DTIC, 200 mg (days 1-3); ACNU, 80 mg (day 1); tamoxifen, 20 mg (P.O. days 1-28).

The size of the metastatic liver tumor decreased after one course of DAV chemotherapy, but it soon grew larger despite an additional two courses of DAC-tam chemotherapy (Fig. 5). Considering the advanced age of the patient, aggressive chemotherapy was avoided and administration of OK432 was started. OK432 is a biologic response modifier consisting of a lyophilized powder made from cultures of penicillin-treated, low-Su-strain human *Streptococcus pyogenes* (Picibanil®, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan). Five Klinische Einheit (KE) (1 KE corresponding to 0.1mg of lyophilized bacilli) was injected subcutaneously every 2 weeks. After administration of OK432, the size of the metastatic tumor gradually decreased (Fig. 5). She is alive without any clinical symptoms of tumor at 46 months after the detection of liver metastasis, although the metastasis is still present on ultrasonic and CT examinations.

Figure 5. Changes in the size of the metastatic melanoma of the liver (arrows). The patient is still alive at 46 months after detection of the liver metastasis without tumor progression.
DISCUSSION

The prognosis of oral melanoma patients has been reported to be extremely poor. According to the recent literature, 5-year survival rate for oral melanoma patients was only 0% 28, 6.6% 21, 13.5% 26, 15% 14, 21.8% 29, 25% 8, 30% 11, 35% 27, and 45% 23. We have treated oral melanoma patients since 1980 with the following treatment protocols: (1) surgical resection of intraoral tumors; (2) neck dissection for clinically detected lymph node metastasis; (3) initiation of adjuvant immunochemotherapy with DTIC, ACNU, VCR, and OK432 on the day of surgery; and (4) no biopsy because it could promote metastasis 31. As a result, most patients treated with these methods obtained a good prognosis, while those who underwent preoperative surgical procedures such as incisional biopsy or tooth extraction frequently died of distant metastasis 33.

Distant metastasis from cutaneous malignant melanoma occurs frequently. Various combination chemotherapies have been proposed for metastatic melanoma 1,4,6,12,13. Regimens most widely used are; CDDP, DTIC, bischloroethylnitrosourea (BCNU), and tamoxifen (Dartmouth regimen) 18, or CDDP, vinblastine, and DTIC (CVD regimen) 20, with- or without immunotherapy using interleukin-2 (IL-2) or interferon (IFN) 2,3,19. However, none of them showed significant difference compared to single agent DTIC in overall survival in a phase III study 1,7.

Atkins et al. 3 analyzed 270 patients with metastatic melanoma in eight clinical trials of immunotherapy using high dose IL-2. The overall objective response rate was 16%, with 17 complete responses (6%). They stated that response rate with high dose IL-2 immunotherapy was low, but responders showed longer progression-free duration than responders with chemotherapy, and that high dose IL-2 immunotherapy can achieved durable complete remissions in a small percentage of patients with metastatic melanoma. IL-2 therapy, however, causes various side effects which can be fatal, such as hypotension, oliguria, increasing serum creatinine, pulmonary vascular congestion, and generalized edema.

IFN has shown modest activity for metastatic melanoma as a single agent. In several trials the response rate ranged from 6% to 27% (average 10%-15%) with response durations from one to 60+ months 1. IFN therapy also causes various side effects, such as bone marrow suppression, fever, chill, elevated alanine transaminase /aspartate aminotransferase (ALT/AST), depression, and suicidal ideation.

In Japan, the regimens of DAV (DTIC, ACNU, and vincristine) and DAC-tam (DTIC, ACNU, CDDP, and tamoxifen) or combination of these regimens plus IFN or OK432 are used generally as adjuvant therapy following surgery 16,34. Although the patients presented here did not initially undergo adjuvant therapy after surgery because of advanced age, DAV and DAC-tam chemotherapies were given when liver metastasis occurred 7 months later. These chemotherapies showed only a minor response for a short duration, so OK432 was then administrated as a palliative therapy. However, the metastatic melanoma decreased unexpectedly and she remains progression-free at 46 months after the occurrence of liver metastasis.

Furudoi et al. 10 reported a case of oral melanoma who showed lung metastasis without loco-regional recurrence at 8 years after the initial therapy (surgery followed by 2 courses of DAV chemotherapy). The patient underwent administration of OK432 (5KE/2 weeks) for 6 years after the initial treatment. They stated that OK432 immunotherapy may suppress the growth of metastatic melanoma of the lung for 6 years postoperatively, but by stopping the use of OK432, metastatic tumor may appear clinically 2 years after that.
A microbial immunostimulant OK432 has been studied intensively and used as an anticancer agent for various malignant tumors over the past 30 years in Japan. Kirkwood et al. 17) reported that patients with melanoma have as significant depression of various cytokine production such as interleukin-1 beta, interferon gamma, and tumor necrosis factor alpha at baseline, and that the depression of these cytokines associated with melanoma may be mitigated by treatment with OK432. Although no controlled study has been conducted as to the effect of OK432 for melanoma patients, this agent has been used for head and neck mucosal melanoma by many clinicians in Japan 9,15,22,24,25. Considering the clinical course of the current case and the slight side effect of OK432, we believe that it is worth administering OK432 for patients with metastatic melanoma when there are no other promising therapies, but further trials are necessary to evaluate the effect of OK432 for this disease.

REFERENCES


